



Corrigendum: Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies

Lena H. Nguyen^{1,2} and Angélique Bordey^{1,2*}

¹ Department of Neurosurgery, Yale School of Medicine, Yale University, New Haven, CT, United States, ² Department of Cellular & Molecular Physiology, Yale School of Medicine, Yale University, New Haven, CT, United States

Keywords: neuron migration, tuberous sclerosis complex, focal cortical dysplasia, GATOR1 complex, *in utero* electroporation, mTOR, cortical development, epilepsy

OPEN ACCESS

Edited and reviewed by:

Alfonso Represa,
INSERM U901 Institut de
Neurobiologie de la
Méditerranée, France

*Correspondence:

Angélique Bordey
angelique.bordey@yale.edu

Received: 26 May 2021

Accepted: 28 May 2021

Published: 06 July 2021

Citation:

Nguyen LH and Bordey A (2021)
Corrigendum: Convergent and
Divergent Mechanisms of
Epileptogenesis in mTORopathies.
Front. Neuroanat. 15:715363.
doi: 10.3389/fnana.2021.715363

A Corrigendum on

Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies
by Nguyen, L. H., and Bordey, A. (2021). *Front. Neuroanat.* 15:664695.
doi: 10.3389/fnana.2021.664695

In the original article, there was a mistake in **Table 1** as published.

Three rows of cited work (*Rheb S16H*, Hsieh et al., 2020; *Rheb P37L*, Reijnders et al., 2017, and *Rheb P37L*, Onori et al., 2020) were omitted.

Additionally, one of the cited studies (*Rheb S16H*) had the incorrect reference Zhang et al., 2019. Zhang, L., Huang, T., Teaw, S., and Bordey, A. (2019). Hypervasculartization in mTOR-dependent focal and global cortical malformations displays differential rapamycin sensitivity. *Epilepsia* 60, 1255–1265. doi: 10.1111/epi.15969. Instead, it should be Zhang et al., 2020. Zhang, L., Huang, T., Teaw, S., Nguyen, L. H., Hsieh, L. S., Gong, X., et al. (2020). Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations. *Sci. Transl. Med.* 12:eaay0289. doi: 10.1126/scitranslmed.aay0289.

The corrected **Table 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 1 | Summary of IUE-based rodent models of mTORopathies.

Gene	IUE age, cortical area	Migration defect/ misplacement (M), Cytomegaly (C), Dendrite overgrowth (D)	Synaptic function and electrophysiological properties	Seizure phenotype	Other phenotypes	Pharmacological and/or genetic rescue	References
<i>Pi3k iSH2-p110α</i> (GOF)	E15.5	E18.5: M	–	–	–	–	Konno et al., 2005
<i>Pi3k WT</i>	E14.5	E18.5: M	–	–	–	–	Baek et al., 2015
* <i>Pi3k E545K</i> (GOF)	E14.5	E18.5: M, C	–	–	–	–	Baek et al., 2015
* <i>Pi3k E545K</i> (GOF)	E14-E15, SSC	–	P15-70 L2/3 PN: No change-RMP No change- R_{input} No change-I/O (rheobase) No change-AP voltage threshold	–	–	–	Goz et al., 2020
* <i>Pi3k E545K</i> (GOF)	E14.5, SSC, CC	P24-28: C, D P60: M, C	P24-28, L2/3 PN: ↓ mIPSC frequency ↓ mIPSC amplitude	Spontaneous seizures	P60: ↓ GABAergic interneuron density	Rapamycin , 2 mg/kg every 48 h, P10-P30: rescued C, D, mIPSC frequency; partially rescued GABAergic interneuron density; no rescue of M, mIPSC amplitude	Zhong et al., 2021
<i>Pten</i> (CRISPR/Cas9 KO)	E14-E15 (rat)	P19: M, C, D	P21-P30, L2/3 PN: ↑ mEPSC frequency ↑ sEPSC frequency No change-RMP ↓ R_{input}	–	–	–	Chen et al., 2015
<i>Akt1 WT</i>	E14.5	E16.5, E17.5, E18.5: – enhanced migration	–	–	–	–	Itoh et al., 2016
<i>Akt1 mΔPH</i> (GOF)	E14.5	E16.5, E17.5: M	–	–	–	–	Itoh et al., 2016
<i>Akt3 WT</i>	E14.5	E18.5: M, C P20: M, C	–	~P28: Spontaneous bursts	–	Rapamycin , 3 mg/kg daily, E15.5-E18.5: rescued M, C	Baek et al., 2015
* <i>Akt3 E17K</i> (GOF)	E14.5	E18.5: M, C P20: M, C	–	~P28: Spontaneous seizures	No microglia reactivity	Rapamycin , 3 mg/kg daily, E15.5-E18.5: rescued M, C Rapamycin , 3 mg/kg daily, P1-P3: no rescue of M Reelin siRNA or Foxg1 T271A (LOF) expression: partially rescued M	Baek et al., 2015
<i>Akt3 S472E</i> (GOF)	E14.5	E18.5: M	–	–	–	–	Baek et al., 2015
<i>Tsc1</i> ^{fixed/mutant} , Cre IUE, 2-hit model	E15-16, SSC	P15: C P28: M, C	–	P15: ↓ Seizure threshold	P15, P28: No astroglial reactivity	–	Feliciano et al., 2011
<i>Tsc1</i> (CRISPR/Cas9 KO)	E14	>P21: M, C	–	>P21: Spontaneous seizures	–	–	Lim et al., 2017

(Continued)

TABLE 1 | Continued

Gene	IUE age, cortical area	Migration defect/ misplacement (M), Cytomegaly (C), Dendrite overgrowth (D)	Synaptic function and electrophysiological properties	Seizure phenotype	Other phenotypes	Pharmacological and/or genetic rescue	References
<i>Tsc1</i> (CRISPR/Cas9 KO)	E14-E15, SSC	–	P15-70 L2/3 PN: ↓ RMP (hyperpolarized) ↓ R_{input} ↓ I/O (= ↑ rheobase) ↓ AP voltage threshold	–	–	–	Goz et al., 2020
<i>Tsc2</i> (shRNA KD)	E14	E19: M, C	–	–	–	Rapamycin , 5 mg/kg daily, E15-E18: rescued M, C	Tsai et al., 2014
<i>Tsc2</i> (shRNA KD)	E13.5, E16.5	E18.5, P2: M	–	–	–	Cul5 shRNA KD : rescued M	Moon et al., 2015
<i>Tsc2</i> (CRISPR/Cas9 KO)	E14	E18: M >P21: M, C	–	>P21: Spontaneous seizures	–	Rapamycin , 10 mg/kg daily, starting after seizure onset: rescued C; ↓ seizures	Lim et al., 2017
<i>Rheb WT</i>	E13.5, E14.5, E16.5	E18.5, P0, P2: M	–	–	–	Cul5 shRNA KD : rescued M	Moon et al., 2015
<i>Rheb WT</i>	E14.5, SSC	P0, P7: M	–	>P20: Spontaneous seizures	–	–	Reijnders et al., 2017
<i>Rheb WT</i>	E14.5-E16, mPFC, SSC	P14: M, C, D	–	–	–	–	Sokolov et al., 2018
<i>Rheb WT</i>	E14.5	–	–	No seizures	–	–	Zhao et al., 2019
<i>Rheb S16H</i> (GOF)	E15, mPFC	P8: M	–	–	P0: ↑ Axon growth	4EBP1 F113A (GOF) expression , S6K1/2 shRNA KD , or lithium chloride (GSK3 blocker) , 10 mg/kg daily, E15-E19: rescued axon overgrowth GSK3β^{DN} expression : rescued axon overgrowth; no rescue of M	Gong et al., 2015
<i>Rheb S16H</i> (GOF)	E15.5, mPFC	P0, P7, P28: M P24: C P28-P42: D	P28-P42 L2/3 PN: ↓ Spine density ↓ sEPSC frequency ↑ RMP (depolarized)	–	P7, P21-28: ↓ Autophagy	4EBP1 F113A (GOF) expression : rescued M, C; partially rescued D; restored RMP, sEPSC frequency; no rescue of spine density S6K1/2 shRNA KD : no rescue of M	Lin et al., 2016
<i>Rheb S16H</i> , conditional (+ DCX-Cre; expression in migrating neurons)	E15.5, mPFC	P7: M	–	–	–	–	Lin et al., 2016

(Continued)

TABLE 1 | Continued

Gene	IUE age, cortical area	Migration defect/ misplacement (M), Cytomegaly (C), Dendrite overgrowth (D)	Synaptic function and electrophysiological properties	Seizure phenotype	Other phenotypes	Pharmacological and/or genetic rescue	References
<i>Rheb S16H</i> (GOF)	E15.5, mPFC	P28: C, D >P56: M	–	>P56: Spontaneous seizures	>P56: ↑ Astroglial reactivity No change in GABAergic interneuron density	Rapamycin , 1 mg/kg every 48h, P1-P56: rescued M, C; ↓ seizures	Hsieh et al., 2016
<i>Rheb S16H</i> , conditional (+ tamoxifen-inducible Cre; postnatal expression) *P7 tamoxifen treatment	E15.5, mPFC	>P56: C, no M	–	>P56: Spontaneous seizures	–	–	Hsieh et al., 2016
<i>Rheb S16H</i> (GOF)	E15, mPFC	>P56: M, C	–	>P56: Spontaneous seizures	>P56: ↑ Microglial reactivity	–	Nguyen et al., 2019
<i>Rheb S16H</i> (GOF)	E15, SSC	P14: M, C, D	–	–	P14: ↑ Vascular density	Rapamycin , 0.5 mg/kg every 48h, P1-P14: rescued D; partially rescued M, C; ↓ vascular density	Zhang et al., 2019
<i>Rheb S16H</i> (GOF)	E15, mPFC	>P28: M, C, D	–	>P42 Spontaneous seizures	–	Flna shRNA KD : partially rescued M, C, D; ↓ seizures PTI-125 (Flna modulator) , 6 or 12 mg/kg 2x daily, P8-28: partially rescued C, D PTI-125 (Flna modulator) , 12 mg/kg 2x daily, P8-65: ↓ seizures; no rescue of M PTI-125 , 12 mg/kg 2x daily, P29-54: partially rescued C, D; ↓ seizures	Zhang et al., 2020
<i>Rheb S16H</i> (GOF)	E15.5, mPFC	>P84: M, C	P8-12, L2/3 PN: ↑ h current P26-42, L2/3 PN: ↑ RMP (depolarized) ↓ R_{input} ↓ I/O (= ↑ rheobase) ↑ h current (and ectopic HCN4 expression) ↑ Sag response	>P84: Spontaneous seizures	–	Rapamycin , 1 mg/kg every 48h, P1-P56: ↓ HCN4 expression Kir2.1 expression : ↓ RMP, ↓ I/O, ↓ seizures; no rescue of C, capacitance HCN4^{NF} expression : ↓ RMP, ↓ h current, ↓ sag response, ↓ seizures; no rescue of C, I/O	Hsieh et al., 2020
** <i>Rheb P37L</i> (GOF)	E14.5, SSC	P0, P7: M	–	>P20: Spontaneous seizures	–	–	Reijnders et al., 2017

(Continued)

TABLE 1 | Continued

Gene	IUE age, cortical area	Migration defect/ misplacement (M), Cytomegaly (C), Dendrite overgrowth (D)	Synaptic function and electrophysiological properties	Seizure phenotype	Other phenotypes	Pharmacological and/or genetic rescue	References
** <i>Rheb P37L</i> (GOF)	E14.5, SSC	P30: M, C P25: D	P21-25, L2/3 PN: No change-RMP ↑ Capacitance ↓ R_{membrane} (= ↓ R_{input}) ↓ I/O (= ↑ rheobase) No change-AP voltage threshold P21-25, contralateral, non-transfected L2/3 PN targeted by mutant axons: ↑ I/O, ↑ eEPSC amplitude in response to depolarizing mutant axons	>P21: Spontaneous seizures	P45: ↑ Axon growth	Rapamycin , 1 mg/kg daily, E15.5-E16.5: partially rescued M; no rescue of seizures Rapamycin , 10 mg/kg daily, starting after seizure onset for 7 days: ↓ seizures Rheb P37L deletion (before seizure onset at P14 or after seizure onset): ↓ seizures; no rescue of M Tetanus toxin light chain expression (blocks axonal projection): prevented seizures Tetanus toxin light chain expression (before seizure onset at P14; blocks vesicular release): prevented seizures, I/O changes in contralateral neurons targeted by Rheb Tetanus toxin light chain expression (after seizure onset at P35; blocks vesicular release): ↓ seizures	Onori et al., 2020
<i>Rheb P37L</i> , conditional (+ tamoxifen-inducible Cre; postnatal expression)	E14.5, SSC *P7 or P21 tamoxifen treatment	No M	–	>P35: Spontaneous seizures	–	–	Onori et al., 2020
** <i>Rheb S68P</i> (GOF)	E14.5, SSC	P0, P7: M	–	>P20: Spontaneous seizures	–	–	Reijnders et al., 2017
* <i>Rheb Y35L</i> (GOF)	E14.5	E18.5: M, C P30: C	–	>P30: Spontaneous seizures	–	Rapamycin , 10 mg/kg daily, starting at P45 for 11 days: ↓ seizures	Zhao et al., 2019
<i>mTOR WT</i>	E14.5	P0: No M, C	–	–	–	–	Kassai et al., 2014
<i>mTOR WT</i>	E14	–	–	No seizures	–	–	Lim et al., 2015; Park et al., 2018; Kim et al., 2019
<i>mTOR WT</i>	E15 (rat)	E20: no M	–	–	–	–	Pelorosso et al., 2019

(Continued)

TABLE 1 | Continued

Gene	IUE age, cortical area	Migration defect/ misplacement (M), Cytomegaly (C), Dendrite overgrowth (D)	Synaptic function and electrophysiological properties	Seizure phenotype	Other phenotypes	Pharmacological and/or genetic rescue	References
<i>mTOR SL1+IT</i> (GOF)	E14.5	P0: M, C	–	–	–	Rapamycin , 5 mg/kg, embryonic, or Raptor shRNA KD : rescued M, C S6K1/2 shRNA KD : rescued C	Kassai et al., 2014
<i>mTOR SL1+IT</i> (GOF)	E13.5, SSC	E17.5: M	–	–	–	–	Tarkowski et al., 2019
* <i>mTOR L2427P</i> (GOF)	E14	E18: M >P21: C	–	>P21: Spontaneous seizures	–	Rapamycin , 10 mg/kg daily, starting after seizure onset for 2 weeks: rescued C; ↓ seizures	Lim et al., 2015
* <i>mTOR L2427P</i> (GOF)	E14	–	–	–	>P56: Defective ciliogenesis ↓ Autophagy	Rapamycin , 10 mg/kg daily, starting after seizure onset for 2 weeks: rescued ciliogenesis	Park et al., 2018
* <i>mTOR L2427P</i> (GOF)	E14	E18, P7: M P21: C	P21, L2/3 PN: ↓ Spine density	>P21: Spontaneous seizures	E18: Translational dysregulation	Rapamycin , 5 mg/kg daily, E14-E17: rescued M eIF4E shRNA KD : rescued M, C, spine density; ↓ seizures Metformin (eIF4E inhibitor) , 200 mg/kg daily, P14-56: rescued C; ↓ seizures Metformin , 200 mg/kg daily, P84-114: ↓ seizures ADK shRNA KD or 5-ITU (ADK inhibitor) , 1 or 2.6 mg/kg, 2x daily for 10 days: ↓ seizures	Kim et al., 2019
* <i>mTOR A1459D</i> (GOF)	E14.5	E18.5: M, C	–	–	–	–	Hanai et al., 2017
* <i>mTOR C1483Y</i> (GOF)	E14	E16, E18: M >P56: C	–	>P21: Spontaneous seizures	>P56: Defective ciliogenesis ↓ Autophagy	Rapamycin , 10 mg/kg daily, after seizure onset for 2 weeks: rescued C, ciliogenesis defects Ofd1 shRNA KD : rescued M, ciliogenesis defects; no rescue of C, seizures Wnt5a expression : rescued M	Park et al., 2018
* <i>mTOR C1483Y</i> (GOF)	E14	E18, P7: M P21: C	P21, L2/3 PN: ↓ Spine density	>P21: Spontaneous seizures	E18: Translational dysregulation	Rapamycin , 5 mg/kg daily, E14-E17: rescued M eIF4E shRNA KD : rescued M, C, spine density; ↓ seizures Metformin (eIF4E inhibitor) , 200 mg/kg daily, P14-56: rescued C; ↓ seizures Metformin , 200 mg/kg daily, P84-114: ↓ seizures ADK shRNA KD or 5-ITU (ADK inhibitor) , 1 or 2.6 mg/kg, 2x daily for 10 days: ↓ seizures	Kim et al., 2019

(Continued)

TABLE 1 | Continued

Gene	IUE age, cortical area	Migration defect/ misplacement (M), Cytomegaly (C), Dendrite overgrowth (D)	Synaptic function and electrophysiological properties	Seizure phenotype	Other phenotypes	Pharmacological and/or genetic rescue	References
* <i>mTOR C1483Y</i> (GOF)	E13.5, SSC	E17.5: M, C	–	–	–	–	Tarkowski et al., 2019
* <i>mTOR L1460P</i> (GOF)	E13.5, SSC	E17.5: M, C	–	–	–	–	Tarkowski et al., 2019
* <i>mTOR S2215Y</i> (GOF)	E13.5, SSC	E17.5: M, C	–	–	–	–	Tarkowski et al., 2019
<i>mTOR R2505P</i> (GOF)	E13.5, SSC	E17.5: M, C	–	–	–	–	Tarkowski et al., 2019
<i>mTOR L2427T</i> (GOF)	E13.5, SSC	E17.5: M	–	–	–	–	Tarkowski et al., 2019
* <i>mTOR S2215F</i> (GOF)	E15 (rat)	E20: M P28: C	–	–	–	–	Pelorosso et al., 2019
<i>Stradα</i> (shRNA KD)	E14	E17, E19: M	–	–	–	–	Orlova et al., 2010
<i>Stradα</i> (shRNA KD)	E14	E19: M	–	–	–	Rapamycin , 5mg/kg daily, E15-E19: rescued M	Parker et al., 2013
<i>Depdc5</i> (CRISPR/Cas9 KO)	E14.5	E18.5: M P21-P63: M, C P20-P24: D	P20-P24, L2/3 PN: No change-Spine density ↑ Spine head width No change-sEPSC frequency ↑ sEPSC amplitude ↑ Capacitance ↓ R_{input} ↓ I/O (= ↑ rheobase)	>P21: Spontaneous seizures	–	Rapamycin , 1 mg/kg single injection at E15: rescued M	Ribierre et al., 2018
<i>Depdc5</i> (CRISPR/Cas9 KO)	E13-E14 (rat)	P21-30: C	P21-28, L2/3 PN: No change-RMP ↓ R_{input} Doublet AP firing	>P60: Spontaneous seizures	–	Everolimus , P10-21: rescued C	Hu et al., 2018
<i>Depdc5</i> fixed/mutant, Cre IUE, 2-hit model	E14.5	P15: C P42: M, C, D	–	P42: ↓ Seizure threshold	–	Depdc5 WT or Depdc5 Q542P (GOF) expression: rescued C Depdc5 F164 del (LOF) expression: no rescue of C	Dawson et al., 2020
<i>Npri3</i> (CRISPR/Cas9 KO)	E14	P3: M, C >P35: C	–	>P35: ↑ Cortical excitability ↓ Seizure threshold	–	Rapamycin , 1 mg/kg single injection at E15: rescued M, C	Iflland et al., 2020

The table is organized by position of genes in the PI3K-mTOR pathway and GATOR1 complex, variant, and date of publication. All gene variants activate mTORC1 signaling. Stars in front of gene name denote human de novo somatic (‘) or germline (‘‘) mutations that have been identified in MCD (e.g., HME, FCDII) and epilepsy. All studies were done in mice unless noted otherwise. Targeted cortical areas are listed if they were specified in the original publication. Ages refers to when IUE was performed and the timepoints of pathological and/or behavioral evaluation. GOF, gain-of-function; LOF, loss-of-function; WT, wildtype; KO, knockout; KD, knockdown; E, embryonic day; P, postnatal day; SSC, somatosensory cortex; CC, cingulate cortex; mPFC, medial prefrontal cortex; L2/3 PN, layer 2/3 pyramidal neurons; RMP, resting membrane potential; R_{input} , input resistance; $R_{membrane}$, membrane resistance; I/O, input/output; mIPSC, miniature inhibitory postsynaptic current; mEPSC, miniature excitatory postsynaptic current; sEPSC, spontaneous excitatory postsynaptic current; eEPSC, evoked excitatory postsynaptic current; AP, action potential; DN, dominant negative; NF, non-functional.

REFERENCES

- Baek, S. T., Copeland, B., Yun, E. J., Kwon, S. K., Guemez-Gamboa, A., Schaffer, A. E., et al. (2015). An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development. *Nat. Med.* 21, 1445–1454. doi: 10.1038/nm.3982
- Chen, F., Rosene, J., Che, A., Becker, A., and LoTurco, J. (2015). Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling. *Development* 142, 3601–3611. doi: 10.1242/dev.118836
- Dawson, R. E., Nieto Guil, A. F., Robertson, L. J., Piltz, S. G., Hughes, J. N., and Thomas, P. Q. (2020). Functional screening of GATOR1 complex variants reveals a role for mTORC1 deregulation in FCD and focal epilepsy. *Neurobiol. Dis.* 134:104640. doi: 10.1016/j.nbd.2019.104640
- Feliciano, D. M., Su, T., Lopez, J., Platel, J. C., and Bordey, A. (2011). Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. *J. Clin. Invest.* 121, 1596–1607. doi: 10.1172/jci44909
- Gong, X., Zhang, L., Huang, T., Lin, T. V., Miyares, L., Wen, J., et al. (2015). Activating the translational repressor 4E-BP or reducing S6K-GSK3beta activity prevents accelerated axon growth induced by hyperactive mTOR in vivo. *Hum. Mol. Genet.* 24, 5746–5758. doi: 10.1093/hmg/ddv295
- Goz, R. U., Akgul, G., and LoTurco, J. J. (2020). BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons. *J. Neurophysiol.* 123, 2449–2464. doi: 10.1152/jn.00523.2019
- Hanai, S., Sukigara, S., Dai, H., Owa, T., Horike, S. I., Otsuki, T., et al. (2017). Pathologic active mTOR mutation in brain malformation with intractable epilepsy leads to cell-autonomous migration delay. *Am. J. Pathol.* 187, 1177–1185. doi: 10.1016/j.ajpath.2017.01.015
- Hsieh, L. S., Wen, J. H., Claycomb, K., Huang, Y., Harrsch, F. A., Naegele, J. R., et al. (2016). Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement. *Nat. Commun.* 7:11753. doi: 10.1038/ncomms11753
- Hsieh, L. S., Wen, J. H., Nguyen, L. H., Zhang, L., Getz, S. A., Torres-Reveron, J., et al. (2020). Ectopic HCN4 expression drives mTOR-dependent epilepsy in mice. *Sci. Transl. Med.* 12:eabc1492. doi: 10.1126/scitranslmed.abc1492
- Hu, S., Knowlton, R. C., Watson, B. O., Glanowska, K. M., Murphy, G. G., Parent, J. M., et al. (2018). Somatic Depdc5 deletion recapitulates electroclinical features of human focal cortical dysplasia type IIA. *Ann. Neurol.* 84, 140–146. doi: 10.1002/ana.25272
- Iffland, P. H., Everett, M. E., Cobb-Pitstick, K. M., Bowser, L. E., Barnes, A. E., Babus, J. K., et al. (2020). NPRL3: direct effects on human phenotypic variability, mTOR signaling, subcellular mTOR localization, cortical lamination, and seizure susceptibility. *bioRxiv* doi: 10.1101/2020.12.11.421214
- Itoh, Y., Higuchi, M., Oishi, K., Kishi, Y., Okazaki, T., Sakai, H., et al. (2016). PDK1-Akt pathway regulates radial neuronal migration and microtubules in the developing mouse neocortex. *Proc. Natl. Acad. Sci. U.S.A.* 113, E2955–E2964. doi: 10.1073/pnas.1516321113
- Kassai, H., Sugaya, Y., Noda, S., Nakao, K., Maeda, T., Kano, M., et al. (2014). Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases. *Cell Rep.* 7, 1626–1639. doi: 10.1016/j.celrep.2014.04.048
- Kim, J. K., Cho, J., Kim, S. H., Kang, H. C., Kim, D. S., Kim, V. N., et al. (2019). Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy. *J. Clin. Invest.* 129, 4207–4223. doi: 10.1172/jci127032
- Konno, D., Yoshimura, S., Hori, K., Maruoka, H., and Sobue, K. (2005). Involvement of the phosphatidylinositol 3-kinase/rac1 and cdc42 pathways in radial migration of cortical neurons. *J. Biol. Chem.* 280, 5082–5088. doi: 10.1074/jbc.m408251200
- Lim, J. S., Gopalappa, R., Kim, S. H., Ramakrishna, S., Lee, M., Kim, W. I., et al. (2017). Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia. *Am. J. Hum. Genet.* 100, 454–472. doi: 10.1016/j.ajhg.2017.01.030
- Lim, J. S., Kim, W. I., Kang, H. C., Kim, S. H., Park, A. H., Park, E. K., et al. (2015). Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. *Nat. Med.* 21, 395–400. doi: 10.1038/nm.3824
- Lin, T. V., Hsieh, L., Kimura, T., Malone, T. J., and Bordey, A. (2016). Normalizing translation through 4E-BP prevents mTOR-driven cortical mislamination and ameliorates aberrant neuron integration. *Proc. Natl. Acad. Sci. U.S.A.* 113, 11330–11335. doi: 10.1073/pnas.1605740113
- Moon, U. Y., Park, J. Y., Park, R., Cho, J. Y., Hughes, L. J., and McKenna, J. III, et al. (2015). Impaired Reelin-Dab1 signaling contributes to neuronal migration deficits of tuberous sclerosis complex. *Cell Rep.* 12, 965–978. doi: 10.1016/j.celrep.2015.07.013
- Nguyen, L. H., Mahadeo, T., and Bordey, A. (2019). mTOR hyperactivity levels influence the severity of epilepsy and associated neuropathology in an experimental model of tuberous sclerosis complex and focal cortical dysplasia. *J. Neurosci.* 39, 2762–2773. doi: 10.1523/jneurosci.2260-18.2019
- Onori, M. P., Koene, L. M. C., Schafer, C. B., Nellist, M., de Brito, van Velze, M., et al. (2020). RHEB/mTOR-hyperactivity causing cortical malformations drives seizures through increased axonal connectivity. *bioRxiv* doi: 10.1101/2020.07.08.189399
- Orlova, K. A., Parker, W. E., Heuer, G. G., Tsai, V., Yoon, J., Baybis, M., et al. (2010). STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. *J. Clin. Invest.* 120, 1591–1602. doi: 10.1172/jci41592
- Park, S. M., Lim, J. S., Ramakrishna, S., Kim, S. H., Kim, W. K., Lee, J., et al. (2018). Brain somatic mutations in MTOR disrupt neuronal ciliogenesis, leading to focal cortical dyslamination. *Neuron* 99, 83–97e87. doi: 10.1016/j.neuron.2018.05.039
- Parker, W. E., Orlova, K. A., Parker, W. H., Birnbaum, J. F., Krymskaya, V. P., Goncharov, D. A., et al. (2013). Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. *Sci. Transl. Med.* 5:182ra153. doi: 10.1126/scitranslmed.3005271
- Pelorosso, C., Watrin, F., Conti, V., Buhler, E., Gelot, A., Yang, X., et al. (2019). Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy. *Hum. Mol. Genet.* 28, 3755–3765. doi: 10.1093/hmg/ddz194
- Reijnders, M. R. F., Kouisi, M., van Woerden, G. M., Klein, M., Bralten, J., Mancini, G. M. S., et al. (2017). Variation in a range of mTOR-related genes associates with intracranial volume and intellectual disability. *Nat. Commun.* 8:1052. doi: 10.1038/s41467-017-00933-6
- Ribierre, T., Deleuze, C., Bacq, A., Baldassari, S., Marsan, E., Chipaux, M., et al. (2018). Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy. *J. Clin. Invest.* 128, 2452–2458. doi: 10.1172/jci99384
- Sokolov, A. M., Seluzicki, C. M., Morton, M. C., and Feliciano, D. M. (2018). Dendrite growth and the effect of ectopic Rheb expression on cortical neurons. *Neurosci. Lett.* 671, 140–147. doi: 10.1016/j.neulet.2018.02.021
- Tarkowski, B., Kuchcinska, K., Blazejczyk, M., and Jaworski, J. (2019). Pathological mTOR mutations impact cortical development. *Hum. Mol. Genet.* 28, 2107–2119. doi: 10.1093/hmg/ddz042
- Tsai, V., Parker, W. E., Orlova, K. A., Baybis, M., Chi, A. W., Berg, B. D., et al. (2014). Fetal brain mTOR signaling activation in tuberous sclerosis complex. *Cereb. Cortex* 24, 315–327. doi: 10.1093/cercor/bhs310
- Zhang, L., Huang, T., Teaw, S., and Bordey, A. (2019). Hypervascularization in mTOR-dependent focal and global cortical malformations displays differential rapamycin sensitivity. *Epilepsia* 60, 1255–1265. doi: 10.1111/epi.15969
- Zhang, L., Huang, T., Teaw, S., Nguyen, L. H., Hsieh, L. S., Gong, X., et al. (2020). Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations. *Sci. Transl. Med.* 12:eaay0289. doi: 10.1126/scitranslmed.aay0289
- Zhao, S., Li, Z., Zhang, M., Zheng, H., Ding, J., et al. (2019). A brain somatic RHEB doublet mutation causes focal cortical dysplasia type II. *Exp. Mol. Med.* 51:84. doi: 10.1038/s12276-019-0277-4
- Zhong, S., Zhao, Z., Xie, W., Cai, Y., Zhang, Y., Ding, J., et al. (2021). GABAergic interneuron and neurotransmission are mTOR-dependently disturbed in experimental focal cortical dysplasia. *Mol. Neurobiol.* 58, 156–169. doi: 10.1007/s12035-020-02086-y

Copyright © 2021 Nguyen and Bordey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.